Fig. 3

Cost-effectiveness planes for 25 cycles (25 years) departing from an asymptomatic, cardiovascular disease-free, and recently diagnosed T2DM at baseline with a mean age of 47 years-old (departing from state A). The model considered an age-dependent progressive increase in transition probabilities as described in Table 1. a. sensitivity analysis considering 5% discount rates for costs and effectiveness for each add-on therapy. b. cost-effectiveness chart comparing incremental cost and effectiveness of pioglitazone, SGLT2i, and GLP-1A on top of standard therapy. c. cost-effectiveness acceptability curve